non-Hodgkin lymphoma

SD-OCT may help diagnose primary vitreoretinal lymphoma
March 05, 2018By Laird Harrison
Hyper-reflective subretinal infiltrates visible on spectral domain optical coherence tomography (SD-OCT) could help diagnose primary vitreoretinal lymphoma (PVRL), researchers believe.
CAR T-cell therapies in treating lymphoma: Pros and cons
January 10, 2018By Aine Cryts
Catherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Game-changing gene therapies present cost problems for health execs
October 20, 2017By Tracey Walker
CAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
Four ways health execs can prep for costly CAR-T cell therapies
October 20, 2017By Tracey Walker
With the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
Personalized strategies critical for childhood cancer
December 07, 2015By Bryant Furlow
Next-generation gene sequencing and other advanced technologies for personalized medicine may soon identify biomarkers that will improve treatment response and long-term toxicity risks for childhood cancer patients.
Waldenstrom’s drug shows sustained benefit at 2 years
April 15, 2015By Tracey Walker
Ibrutinib, a newly approved drug for Waldenstrom’s Macroglobulinemia, a rare form of lymphoma, continued to control the rare blood cancer, with 95% of patients surviving for 2 years, according to a new study, published in The New England Journal of Medicine.
FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma
January 30, 2015By Erin Bastick
FDA has approved expanded use of ibrutinib for the treatment of Waldenstroms Macroglobulinemia.
FDA approves bortezomib for injection for previously untreated patients with mantle cell lymphoma
October 14, 2014By Tracey Walker
FDA approved bortezomib (Velcade, Millennium: The Takeda Oncology Company) for injection for use in previously untreated patients with mantle cell lymphoma (MCL), making it the first treatment in the United States to be approved for previously untreated patients with MCL.
FDA drug approvals-August 2014
August 01, 2014By Tracey Walker
FDA actions in brief, complete response, fast-track designation, priority review, orphan drug designations, first-time generic approval
FDA drug approvals-July 2014
July 01, 2014By Tracey Walker
FDA drug approvals, priority review, breakthrough designation, fast-track designations, orphan drug designations, first-time generic approval